Glucotrack, Inc. — Form 8-K/A
Filed August 28, 2026 · analyzed by the 8-K Agent
8-K/A
▼ Likely negative
significance 78/100
What the filing says
On July 14, 2026, Lokahi Therapeutics (a bee-venom biopharmaceutical development company) merged into Glucotrack, Inc. Lokahi shareholders received 1,311,200 common shares and 785,334 Series A preferred shares (convertible into 100 common shares each), yielding 90% ownership on a fully diluted basis. Purchase price allocation: $32.2M ($25.4M in-process R&D, $13.5M goodwill). Lokahi had $53.2K cash, $9.1M current liabilities, $6.7M accumulated deficit, and substantial going-concern doubt as of June 30, 2026. Pro forma six-month net loss: $19.7M.
Why this rating
Material for Lokahi (5.4M cap): $32M acquisition price ≈ 600% of pre-merger equity value; merger dilutes existing holders 90%. For Glucotrack: major balance-sheet impact (goodwill, intangibles, liabilities). Going-concern warnings, high burn rate ($8.1M loss in 6 mo.), and underfunded clinical pipeline pose severe risk.
Tradability signal
NO TRADE
No trade: price $0.29 is below our $0.5 floor — spreads at this level eat any edge.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
before filing · preread $0.29 ▲ 0.00% | at our read · backfill $0.29 | +10 min · backfill $0.29 ▼ 0.93% | +30 min · backfill $0.27 ▼ 5.21% | +1 hr · backfill $0.28 ▼ 4.83% |
The stock had already moved +0.00% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from August 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.